Jefferies Financial Group Reiterates “Buy” Rating for Qiagen (NYSE:QGEN)

Jefferies Financial Group restated their buy rating on shares of Qiagen (NYSE:QGEN) in a research report released on Tuesday, Marketbeat.com reports. They currently have a $54.00 price target on the stock, up from their previous price target of $42.00.

QGEN has been the topic of several other research reports. HSBC cut shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective on the stock. in a research note on Thursday, October 17th. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research report on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $51.15.

Qiagen Stock Performance

Shares of Qiagen stock opened at $46.07 on Tuesday. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39. Qiagen has a twelve month low of $39.03 and a twelve month high of $47.44. The stock has a market cap of $10.51 billion, a price-to-earnings ratio of 118.13, a P/E/G ratio of 3.37 and a beta of 0.35. The company’s fifty day moving average is $43.09 and its 200 day moving average is $43.66.

Hedge Funds Weigh In On Qiagen

A number of institutional investors and hedge funds have recently made changes to their positions in QGEN. Wellington Management Group LLP boosted its position in shares of Qiagen by 77.7% during the 3rd quarter. Wellington Management Group LLP now owns 21,250,943 shares of the company’s stock worth $963,386,000 after purchasing an additional 9,293,040 shares in the last quarter. Victory Capital Management Inc. boosted its position in shares of Qiagen by 104,759.6% during the 2nd quarter. Victory Capital Management Inc. now owns 1,583,380 shares of the company’s stock worth $65,061,000 after purchasing an additional 1,581,870 shares in the last quarter. Barclays PLC boosted its position in shares of Qiagen by 170.6% during the 3rd quarter. Barclays PLC now owns 1,849,004 shares of the company’s stock worth $84,259,000 after purchasing an additional 1,165,594 shares in the last quarter. Nuance Investments LLC boosted its position in shares of Qiagen by 17.3% during the 2nd quarter. Nuance Investments LLC now owns 5,271,494 shares of the company’s stock worth $216,606,000 after purchasing an additional 778,005 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its position in shares of Qiagen by 148.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,184,806 shares of the company’s stock worth $48,684,000 after purchasing an additional 708,533 shares in the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.